Dr. Shaoqiang Cheng 程绍强
Chief Physician
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and cosmetic surgery for benign breast tumors, breast-conserving surgery, modified radical mastectomy, and individualized comprehensive treatment for breast cancer.
Dr. Cheng graduated from Harbin Medical University in 2001. After training in Japan, Dr. Cheng earned a PhD in Surgical Oncology from Hokkaido University in 2008 and joined the Breast Surgery Department at Harbin Medical University Cancer Hospital. Dr. Cheng leads multiple research projects and has published six SCI-indexed papers.
Professional roles
- Member, Chinese Medical Doctor Association
- Member, Heilongjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Cheng Shaoqiang). Papers usually list the name as Shaoqiang Cheng or Cheng S.
Selected publications
12 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Dis, 2026 (first author): A Lamp2a-linked RNA secreted by ADSCs prevents ENO1-lactylation-glycolysis feedback and cell malignant behavior in triple-negative breast cancer. PubMed 41771848
- Breast, 2025 (senior author): Novel models based on machine learning to predict the prognosis of metaplastic breast cancer. PubMed 39675092
- Front Oncol, 2023 (senior author): Predictive value of controlling nutritional status score in postoperative recurrence and metastasis of breast cancer patients with HER2-low expression. PubMed 37492470
- Front Oncol, 2022 (senior author): Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study. PubMed 36686748
- Transl Oncol, 2022 (senior author): Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer. PubMed 35121221
- Cancer Cell Int, 2021 (first author): Retraction Note to: Long non-coding RNA SATB2-AS1 inhibits microRNA-155-3p to suppress breast cancer cell growth by promoting breast cancer metastasis suppressor 1-like. PubMed 33583393
- Cancer Cell Int, 2020 (first author): Long non-coding RNA SATB2-AS1 inhibits microRNA-155-3p to suppress breast cancer cell growth by promoting breast cancer metastasis suppressor 1-like. PubMed 32694943
- Cancer Biol Ther, 2019 (first author): FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation. PubMed 30336071
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion